PITTSBURGH , March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . , (“ Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene